The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
you look at the cox-2 Inhibitors you look at Celebrex versus viox I mean notwithstanding my views on that which I talk about with Eric tople on our podcast but um you know basically Two drugs nearly identical and one was far more efficacious but also had uh side effects in a subset of people with hypertension
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.